Amicus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
PRINCETON, N.J., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that Bradley Campbell, President…
9,250€
-1,60%
Echtzeit-Aktienkurs Amicus Therapeutics
Bid:
Ask:
Nachrichten zur Amicus Therapeutics Aktie
Amicus Therapeutics: Cheap Heading Into 2025
…
Amicus Therapeutics to Announce Third Quarter 2024 Financial Results on November 6, 2024
PRINCETON, N.J., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will…
Amicus Therapeutics (FOLD) Stock Jumps 14.0%: Will It Continue to Soar?
Amicus Therapeutics (FOLD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings…
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2024
PRINCETON, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate…
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2024
PRINCETON, N.J., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate…
Amicus Therapeutics: A Compelling Investment In The Rare Disease Biotech Sector
…
Amicus Therapeutics, Inc. 2024 Q2 - Results - Earnings Call Presentation
…
Amicus Therapeutics, Inc. (FOLD) Q2 2024 Earnings Call Transcript
…
Amicus Therapeutics: Too Cheap At Under $10 A Share
…
Earnings call: Amicus Therapeutics highlights solid Q1 growth, raises guidance By Investing.com
Earnings call: Amicus Therapeutics highlights solid Q1 growth, raises guidance…
Amicus Therapeutics, Inc. (FOLD) Q1 2024 Earnings Call Transcript
…
Amicus Therapeutics, Inc. (FOLD) Q4 2023 Earnings Call Transcript
…
Time to Buy These 3 Healthcare Companies That Raised Revenue Guidance?
Stocks Analysis by MarketBeat.com (Jea Yu) covering: Hologic Inc, EXACT Sciences Corporation, Amicus Therapeutics Inc. Read MarketBeat.com (Jea Yu)s latest…
Amicus Therapeutics sees 2023 revenue growth of 21% Y/Y; issues 2024 strategic outlook
…
Amicus Therapeutics Inc. (FOLD) Q3 2023 Earnings Call Transcript
…
Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2023
PRINCETON, N.J., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate…
Amicus Therapeutics: The Right Play Now
…
Amicus Therapeutics and Blackstone Enter into $430 Million Strategic Financing Collaboration
Refinancing of Current $400M Debt at Lower Cost and Improved Amortization Schedule…
Aimed Alliance: Groups File Amicus Brief to Shed Light on Harmful Drug Sourcing Tactics
Health care providers and consumer organizations inform federal court of the harms caused by alternative funding programs.WASHINGTON, DC / ACCESSWIRE…
US thinktank linked to billionaires behind supreme court wealth tax case lobbying
Manhattan Institute one of eight conservative advocacy groups that filed amicus briefs urging the court to hear Moore v USAn…
Amicus Therapeutics Appoints Simon Harford as Chief Financial Officer
Daphne Quimi to Retire At Year End...…
Form 8-K AMICUS THERAPEUTICS, For: Aug 17
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Amicus announces U.K. approval and launch of Pompe disease therapy
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the United Kingdom
Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) Approved for Adults Living with Late-Onset Pompe Disease in Great Britain...…
Form 8-K AMICUS THERAPEUTICS, For: Aug 15
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Amicus Therapeutics (FOLD) Reports Q2 Loss, Tops Revenue Estimates
Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -25% and 5.51%, respectively, for the quarter ended June 2023. Do…
Amicus Therapeutics reports mixed Q2 earnings; updates FY23 outlook
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Form 8-K AMICUS THERAPEUTICS, For: Aug 03
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Amicus Therapeutics Q2 2023 Earnings Preview
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Why Earnings Season Could Be Great for Amicus Therapeutics (FOLD)
Amicus Therapeutics (FOLD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings…
3 Top Breakout Stocks to Invest in for Excellent Returns
First Watch Restaurant Group (FWRG), VersaBank (VBNK), and Amicus Therapeutics (FOLD) have been selected as the breakout stocks for today....…
Justice Jackson Accused Of Second Glaring False Claim In Affirmative Action Dissent
Justice Jackson Accused Of Second Glaring False Claim In Affirmative Action Dissent
…
Insiderhandel: Executive Chairman verkauft Aktien von Amicus Therapeutics im Wert von 81.263$
Crowley, John F. - Vorstand - Tag der Transaktion: 2023-07-17...…
Form 8-K AMICUS THERAPEUTICS, For: Jul 10
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Insiderhandel: Executive Chairman verkauft Aktien von Amicus Therapeutics im Wert von 74.406$
Crowley, John F. - Vorstand - Tag der Transaktion: 2023-07-03...…
Insiderhandel: President & CEO verkauft Aktien von Amicus Therapeutics im Wert von 144.016$
Campbell, Bradley L. - Vorstand - Tag der Transaktion: 2023-07-03...…
Amicus (FOLD) Gets Approval in Europe for Pompe Disease Drug
Amicus (FOLD) receives approval for Opfolda (miglustat) from the European Commission to treat the adult late-onset Pompe disease....…
Form 8-K AMICUS THERAPEUTICS, For: Jun 27
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Amicus Therapeutics wins EC approval of Opfolda for Pompe disease
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Insiderhandel: Executive Chairman verkauft Aktien von Amicus Therapeutics im Wert von 78.814$
Crowley, John F. - Vorstand - Tag der Transaktion: 2023-06-15...…
Form 8-K AMICUS THERAPEUTICS, For: Jun 08
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Why Is Amicus Therapeutics (FOLD) Up 8.1% Since Last Earnings Report?
Amicus Therapeutics (FOLD) reported earnings 30 days ago. Whats next for the stock? We take a look at earnings estimates…
Insiderhandel: President & CEO verkauft Aktien von Amicus Therapeutics im Wert von 103.777$
Campbell, Bradley L. - Vorstand - Tag der Transaktion: 2023-06-06...…
Insiderhandel: Executive Chairman verkauft Aktien von Amicus Therapeutics im Wert von 68.657$
Crowley, John F. - Vorstand - Tag der Transaktion: 2023-06-01...…
Insiderhandel: President & CEO verkauft Aktien von Amicus Therapeutics im Wert von 132.942$
Campbell, Bradley L. - Vorstand - Tag der Transaktion: 2023-06-01...…
Female Athlete Retires After Competing Against Biological Men, Says Girls "No Longer Have A Fair Chance"
Female Athlete Retires After Competing Against Biological Men, Says Girls "No Longer Have A Fair Chance"
…
Insiderhandel: Executive Chairman verkauft Aktien von Amicus Therapeutics im Wert von 67.577$
Crowley, John F. - Vorstand - Tag der Transaktion: 2023-05-15...…
New York AG Letitia James leads multi-state effort defending CFPB to the Supreme Court
Attorneys general of 22 other states and the District of Columbia joined James in filing an amicus brief to the…
Form 8-K AMICUS THERAPEUTICS, For: May 10
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…